Can Upadatinib/Refu effectively treat skin diseases such as eczema?

Upadacitinib (Upadacitinib) is a highly selective JAK inhibitor that was initially used for immune-inflammation-related diseases. With in-depth research, its application in the field of dermatology has gradually attracted attention. Currently, the drug has been approved for use as a second-line treatment for patients aged 12 years and older with refractory, moderate to severe atopic dermatitis (AD), providing a new option for people whose traditional treatment results are unsatisfactory.

From the perspective of its mechanism of action, atopic dermatitis is a chronic inflammatory skin disease centered on immune imbalance, and a variety of inflammatory factors are involved in the pathogenesis. Upadatinib inhibits the JAK signaling pathway and blocks the transmission of a variety of cytokines related to inflammatory response, itching and skin barrier damage, thereby reducing the inflammatory response from the source.

In the medication experience, upadatinib is considered to be more effective in improving skin inflammation and relieving itching. After continued use of the drug, many patients have seen improvement in the extent of skin lesions, degree of erythema, and nighttime itching, and the impact on sleep quality and daily life has been significantly reduced. This is especially important for patients who have been troubled by eczema for a long time and have a heavy psychological burden.

Compared with traditional topical drugs or immunosuppressants, upadatinib is an oral small molecule targeted drug, which is relatively simple to use and does not rely on injection routes, which improves patient acceptance. For patients with moderate to severe atopic dermatitis who do not respond well to topical corticosteroids or who have frequent relapses, upadatinib can be an important addition to systemic therapy.

It should be noted that upadatinib is usually positioned as a second-line treatment option and is suitable for patients with limited efficacy or intolerance to conventional treatments. During the medication process, doctors will conduct individualized assessments based on the patient's age, severity of illness, and comorbid conditions, and conduct regular follow-up visits to ensure the safety of medication.

Keyword tag: Upatinib Atopic dermatitis Eczema Ruifu Skin disease JAK inhibitor second-line treatment oral targeted drug

Reference materials:https://www.drugs.com/upadacitinib.html